{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-001009","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.068142+00:00","generated_at":"2026-06-06T00:59:30.554766+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sunshine Biopharma closes ~$10M underwritten public offering of units with warrants","bullets":["71,428,571 Units priced at $0.14/Common Unit and $0.139/Pre-Funded Unit; gross proceeds ~$10.0M.","Each Unit includes common stock (or pre-funded warrant) plus 0.1 Series A ($2.10 strike) and 0.2 Series B ($2.38 strike) warrants.","Underwriter Aegis Capital Corp. partially exercised over-allotment for 2,491,071 Series A and B warrants.","Net proceeds earmarked for general corporate purposes and working capital.","Offering closed on February 15, 2024; warrants expire in 30 months (Series A) and 60 months (Series B)."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-001009","json":"https://secwatch.observer/filing/0001683168-24-001009.json","markdown":"https://secwatch.observer/filing/0001683168-24-001009.md","text":"https://secwatch.observer/filing/0001683168-24-001009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/0001683168-24-001009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:59:30.554766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34ada46510d72cbf0e745cff8f11bee02382364a","claim":"Sunshine Biopharma Inc. entered into Underwriting Agreement with Aegis Capital Corp. valued at approximately $10.0 million (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, Sunshine Biopharma, Inc., (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (the “Underwriter”), in connection with a firm commitment underwritten public offering (the “Offering”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/0001683168-24-001009-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Aegis Capital Corp."},{"label":"Value","value":"approximately $10.0 million"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}